ClinicalTrials.gg
CompletedNCT01189890Updated Jun 5, 2017Results posted

Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

A Phase 3 interventional study of sitagliptin phosphate and Glimepiride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 65 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-06-05.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
65 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
34th of 197
480 · median 102
Started
2010
with 22 others
Phase 3
74 of 198
none open now
Registered
93rd of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 34th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 74 in phase 3, and was the 93rd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 65 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin treatment results in a lower incidence of symptomatic hypoglycemia compared to that of glimepiride. The study will also evaluate if sitagliptin treatment, compared to glimepiride results in improvements in fasting plasma glucose (FPG) levels, and plasma lipid levels after 30 weeks of treatment. Participants will be randomized to either sitagliptin or glimepiride treatment after eligibility for study participation is determined during screening and washout study phases. Participants and study staff will not know to which treatment group they have been randomized (double-blind design). The duration of study participation will be up to 40 weeks (with 9 clinic visits). This will include a screening phase (Visit 1 to Visit 2) of 2 weeks maximum; a 6-week (Visits 2 to 3) oral antihyperglycemic agent (AHA) wash-out phase (for those who have been taking a AHA prior to the study); a placebo run-in phase (Visits 3 to 4), followed by up to 30 weeks of treatment with study medication.

Read the detailed description

The dose of sitagliptin will be 100 mg once daily (QD) or 50 mg QD based on the participant's estimated glomerular filtration rate (eGFR). The starting dose of glimepiride (1 mg QD) may be up-titrated as needed to optimize glycemic control over the first 18 weeks to a maximum dose of 6 mg/day, after which the dose will not be increased for the rest of the study (down-titration to avoid or control hypoglycemia is allowed).

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus, Hemoglobin A1C, glucagon-like peptide 1 (GLP-1), gastric inhibitory polypeptide (GIP), dipeptidyl peptidase 4 inhibitor (DPP-4)
04

Who can participate

Ages eligible
65 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria

  • History of type 1 diabetes mellitus
  • Has undergone a surgical procedure within the prior 4 weeks.
  • Current participation in, or has participated, in another study with an device or compound, with the prior 12 weeks, and/or is not willing to refrain from participating in any other study while participating in this study
  • or to any sulfonylurea (e.g., glimepiride) medication
  • Has been on an investigational or approved dipeptidyl peptidase-4 (DPP-4) inhibitor agent (e.g., sitagliptin, saxagliptin)
  • Presence of (HIV)
  • Current participation in a weight loss program or is receiving weight loss medication
  • History of blood disorder, certain cancers, heart, liver or kidney disease
  • Current or past use of recreational or illicit drugs, or a history of drug abuse or dependence, or increased alcohol consumption
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin phosphate 100 mg or 50 mg once daily (QD)

    Drug: sitagliptin phosphate · Drug: Placebo to Glimepiride

  • Active comparator
    Glimepiride

    Glimepiride 1-6 mg QD

    Drug: Glimepiride · Drug: Placebo to Sitagliptin

Interventions

  • Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.

    Also known as: Januvia

  • Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.

    Also known as: Amaryl

  • DrugPlacebo to Sitagliptin

    Matching placebo tablets to sitagliptin to allow for blinding.

  • DrugPlacebo to Glimepiride

    Matching placebo tablets to glimepiride to allow for blinding.

06

What researchers measure

Primary outcomes

  1. Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30

    Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

    Time frame: Baseline and Week 30

  2. Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30

    Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.

    Time frame: Up to Week 30

  3. Number of Participants Experiencing An Adverse Event (AE)

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.

    Time frame: Up to Week 30

  4. Number of Participants Discontinuing Study Treatment Due to An AE

    An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.

    Time frame: Up to Week 30

Secondary outcomes

  1. LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

    Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.

    Time frame: Baseline and Week 30

  2. Percentage of Participants With HbA1c <7.0% at Week 30

    Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

    Time frame: Week 30

  3. Percentage of Participants With HbA1c <6.5% at Week 30

    Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

    Time frame: Week 30

  4. LS Mean Change From Baseline in Participant Body Weight at Week 30

    Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.

    Time frame: Baseline and Week 30

07

Results

Posted Jun 27, 2013

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinGlimepiride
Started241239
Completed204200
Not completed3739
Withdrew: Adverse event34
Withdrew: Lack of efficacy72
Withdrew: Lost to follow-up17
Withdrew: Protocol violation15
Withdrew: Withdrawal by subject1511
Withdrew: Non compliance01
Withdrew: Physician decision54
Withdrew: Hyperglycemia discontinuation criteria55

Outcome measures

PrimaryLeast Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30

Participant whole blood samples were collected at baseline and Week 30 to determine the LS mean HbA1c change from baseline. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · Percentage of HbA1c
Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30
Percentage of HbA1cSitagliptinGlimepiride
Least Squares (LS) Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 30-0.32 ± 0.78-0.51 ± 0.89
Statistical analysis
  • Sitagliptin vs Glimepiride · ANCOVA · Difference in ls means: 0.19 · 95% CI 0.03 to 0.34Controlled for treatment, estimated glomerular filtration rate (eGFR) stratum, age stratum, and baseline HbA1C.
PrimaryNumber of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30

Symptomatic hypoglycemia was defined as an episode with clinical symptoms attributed to hypoglycemia, without regard to glucose level. Participants were instructed to complete the Hypoglycemia Assessment Log (HAL) for any symptomatic episodes he or she believed represent hypoglycemia. If a fingerstick glucose was obtained before or shortly (i.e., within a few minutes) after treating, the value was recorded in the HAL. In addition, participants were instructed to record in the HAL any fingerstick glucose values ≤70 mg/dL (≤3.9 mmol/L) regardless of the presence of clinical symptoms.

Time frame:
Up to Week 30
Reported as:
Number · Participants
Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30
ParticipantsSitagliptinGlimepiride
Number of Participants With an Adverse Event of Symptomatic Hypoglycemia Up to Week 30211
Statistical analysis
  • Sitagliptin vs Glimepiride · Miettinen & Nurminen · p = 0.009 · Difference in percent incidence: -3.9 · 95% CI -7.5 to -1.2Stratified by estimated glomerular filtration rate (eGFR) stratum and age stratum.
PrimaryNumber of Participants Experiencing An Adverse Event (AE)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.

Time frame:
Up to Week 30
Reported as:
Number · Participants
Number of Participants Experiencing An Adverse Event (AE)
ParticipantsSitagliptinGlimepiride
Number of Participants Experiencing An Adverse Event (AE)118115
PrimaryNumber of Participants Discontinuing Study Treatment Due to An AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study treatment, whether or not considered related to the use of the treatment administered.

Time frame:
Up to Week 30
Reported as:
Number · Participants
Number of Participants Discontinuing Study Treatment Due to An AE
ParticipantsSitagliptinGlimepiride
Number of Participants Discontinuing Study Treatment Due to An AE34
SecondaryLS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30

Plasma samples were collected from participants after an overnight fast at baseline and Week 30 to determine the mean change from baseline in participant FPG.

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · mg/dL
LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30
mg/dLSitagliptinGlimepiride
LS Mean Change From Baseline in Fasting Plasma Glucose (FPG) at Week 30-14.5 ± 39.0-21.2 ± 39.1
Statistical analysis
  • Sitagliptin vs Glimepiride · ANCOVA · Difference in ls means: 6.7 · 95% CI 0.7 to 12.7Controlled for treatment, eGFR stratum, age stratum, and baseline FPG.
SecondaryPercentage of Participants With HbA1c <7.0% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<7.0% at Week 30. HbA1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

Time frame:
Week 30
Reported as:
Number · Percentage of Participants
Percentage of Participants With HbA1c <7.0% at Week 30
Percentage of ParticipantsSitagliptinGlimepiride
Percentage of Participants With HbA1c <7.0% at Week 3033.546.6
Statistical analysis
  • Sitagliptin vs Glimepiride · Miettinen & Nurminen · Relative risk: 0.7 · 95% CI 0.6 to 0.9Stratified by eGFR stratum and age stratum.
SecondaryPercentage of Participants With HbA1c <6.5% at Week 30

Participant whole blood samples were collected at Week 30 to determine the number of participants achieving HbA1c \<6.5% at Week 30. Hemoglobin A1c is a measure of the percentage of glycated hemoglobin in the blood and provides an indication of participant blood glucose control in the 2 to 3 months prior to the evaluation.

Time frame:
Week 30
Reported as:
Number · Percentage of Participants
Percentage of Participants With HbA1c <6.5% at Week 30
Percentage of ParticipantsSitagliptinGlimepiride
Percentage of Participants With HbA1c <6.5% at Week 309.120.9
Statistical analysis
  • Sitagliptin vs Glimepiride · Miettinen & Nurminen · Relative risk: 0.4 · 95% CI 0.3 to 0.7Stratified by eGFR stratum and age stratum.
SecondaryLS Mean Change From Baseline in Participant Body Weight at Week 30

Participants were only permitted to wear a drape gown and undergarments (no street clothes, no shoes or socks) for this evaluation. Body weight was measured after voiding (to the nearest 0.1 kg) and measurements were collected until 2 consecutive measurements did not differ by more than 0.2 kg from each other. Body weight measurements were evaluated using a standardized, calibrated digital scale and was reported in kilograms (kg) at baseline and Week 30.

Time frame:
Baseline and Week 30
Reported as:
Least squares mean · kg
LS Mean Change From Baseline in Participant Body Weight at Week 30
kgSitagliptinGlimepiride
LS Mean Change From Baseline in Participant Body Weight at Week 300.4 ± 3.21.1 ± 2.8
Statistical analysis
  • Sitagliptin vs Glimepiride · ANCOVA · p = 0.011 · Difference in ls means: -0.7 · 95% CI -1.3 to -0.2Controlled for treatment, eGFR stratum, age stratum, and baseline body weight.

Adverse events

Collected over Up to Week 32.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—7/241 (2.9%)34/241 (14.1%)
Glimepiride—6/236 (2.5%)40/236 (16.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSitagliptinGlimepiride
AnaemiaBlood and lymphatic system disorders0/2411/236
Angina UnstableCardiac disorders0/2411/236
Cardiac Failure ChronicCardiac disorders0/2411/236
Gastrointestinal HaemorrhageGastrointestinal disorders0/2411/236
Nerve CompressionNervous system disorders0/2411/236
SyncopeNervous system disorders0/2411/236
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders0/2411/236
Atrial FibrillationCardiac disorders1/2410/236
Inguinal HerniaGastrointestinal disorders1/2410/236
Lower Gastrointestinal HaemorrhageGastrointestinal disorders1/2410/236
Most frequent other events
Most frequent other events
EventSitagliptinGlimepiride
NasopharyngitisInfections and infestations18/24119/236
HypoglycaemiaMetabolism and nutrition disorders3/24115/236
HyperglycaemiaMetabolism and nutrition disorders14/2419/236

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinGlimepirideTotal
Mean70.7 ± 4.870.8 ± 4.970.7 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinGlimepirideTotal
Female130148278
Male11191202
Hemoglobin A1c (HbA1c)
Hemoglobin A1c (HbA1c)(Percentage of HbA1c)SitagliptinGlimepirideTotal
Mean7.78 ± 0.707.78 ± 0.677.78 ± 0.69
Fasting Plasma Glucose (FPG)
Fasting Plasma Glucose (FPG)(mg/dL)SitagliptinGlimepirideTotal
Mean168.4 ± 31.2169.7 ± 35.5169.0 ± 33.3
Body Weight
Body Weight(kg)SitagliptinGlimepirideTotal
Mean76.9 ± 15.175.4 ± 16.476.0 ± 15.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hartley P, Shentu Y, Betz-Schiff P, Golm GT, Sisk CM, Engel SS, Shankar RR. Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial. Drugs Aging. 2015 Jun;32(6):469-76. doi: 10.1007/s40266-015-0271-z. PubMed 26041585 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2010 to primary completion in Oct 2012, 26 months.

Results were first posted in Jun 2013, 7 months after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2010
First posted
Aug 27, 2010
StartActual
Aug 16, 2010
Primary completionActual
Oct 31, 2012
CompletionActual
Oct 31, 2012
Results first posted
Jun 27, 2013
Last update
Jun 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01189890
Responsible party
Sponsor
First posted
Aug 27, 2010
Start date
Aug 16, 2010
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012
Results posted
Jun 27, 2013
Last update
Jun 5, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion